Display options
Cite
Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel). 2010;3(4):1122-1138doi: 10.3390/ph3041122.
Ferraldeschi, R., & Newman, W. G. (2010). The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel, Switzerland), 3(4), 1122-1138. https://doi.org/10.3390/ph3041122
Ferraldeschi, Roberta, and Newman, William G. "The Impact of CYP2D6 Genotyping on Tamoxifen Treatment." Pharmaceuticals (Basel, Switzerland) vol. 3,4 (2010): 1122-1138. doi: https://doi.org/10.3390/ph3041122
Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122-1138. doi: 10.3390/ph3041122. PMID: 27713292; PMCID: PMC4034025.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122-1138. doi: 10.3390/ph3041122.

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment.

Pharmaceuticals (Basel, Switzerland)

Roberta Ferraldeschi, William G Newman

Affiliations

  1. Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. [email protected].
  2. Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK. [email protected].
  3. Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK. [email protected].

PMID: 27713292 PMCID: PMC4034025 DOI: 10.3390/ph3041122

Abstract

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in

Keywords: CYP2D6 genotyping; breast cancer; tamoxifen

References

  1. Oncogene. 2006 Mar 13;25(11):1679-91 - PubMed
  2. Breast Cancer Res. 2005;7(3):R284-90 - PubMed
  3. Clin Pharmacol Ther. 2008 May;83(5):702-10 - PubMed
  4. J Clin Oncol. 2010 Jan 20;28(3):509-18 - PubMed
  5. Breast Cancer Res Treat. 2009 Nov;118(1):125-30 - PubMed
  6. J Pharmacol Exp Ther. 2006 Aug;318(2):503-12 - PubMed
  7. Clin Cancer Res. 2009 Jan 1;15(1):15-21 - PubMed
  8. Clin Pharmacol Ther. 2006 Jul;80(1):61-74 - PubMed
  9. Drug Metab Dispos. 2007 Nov;35(11):2006-14 - PubMed
  10. Biochem Pharmacol. 2006 Apr 28;71(9):1358-69 - PubMed
  11. Ann Oncol. 2008 Aug;19(8):1423-9 - PubMed
  12. Breast Cancer Res Treat. 2005 Jun;91(3):249-58 - PubMed
  13. J Clin Oncol. 2009 Jun 10;27(17):2831-7 - PubMed
  14. Cancer Res. 2009 Mar 1;69(5):1722-7 - PubMed
  15. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64 - PubMed
  16. Am Fam Physician. 2007 Aug 1;76(3):391-6 - PubMed
  17. J Clin Oncol. 2002 Mar 15;20(6):1578-83 - PubMed
  18. Breast Cancer Res Treat. 2007 Jan;101(1):113-21 - PubMed
  19. Clin Cancer Res. 2008 Sep 15;14(18):5913-8 - PubMed
  20. Breast J. 2006 Mar-Apr;12(2):114-22 - PubMed
  21. Breast Cancer Res Treat. 2010 Jan;119(1):33-8 - PubMed
  22. Nat Rev Cancer. 2009 Aug;9(8):576-86 - PubMed
  23. J Natl Cancer Inst. 2008 May 7;100(9):642-8 - PubMed
  24. Biochem Pharmacol. 2002 May 15;63(10):1817-30 - PubMed
  25. Breast Cancer Res. 2007;9(1):R7 - PubMed
  26. BMJ. 2010 Feb 08;340:c693 - PubMed
  27. JAMA. 2009 Oct 7;302(13):1429-36 - PubMed
  28. J Clin Oncol. 2009 Feb 20;27(6):840-2 - PubMed
  29. Pharmacogenomics. 2002 Mar;3(2):229-43 - PubMed
  30. Anal Bioanal Chem. 2008 Nov;392(6):1093-108 - PubMed
  31. J Endocrinol. 1977 Nov;75(2):305-16 - PubMed
  32. Cancer Sci. 2008 May;99(5):995-9 - PubMed
  33. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2562-4 - PubMed
  34. Breast Cancer Res Treat. 2009 Jun;115(3):643-50 - PubMed
  35. Br J Clin Pharmacol. 2002 Aug;54(2):157-67 - PubMed
  36. J Natl Compr Canc Netw. 2009 Feb;7(2):203-13 - PubMed
  37. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003370 - PubMed
  38. J Clin Oncol. 2007 Sep 1;25(25):3837-45 - PubMed
  39. Pharmacogenomics J. 2009 Aug;9(4):258-64 - PubMed
  40. Pharmacogenomics J. 2005;5(1):6-13 - PubMed
  41. Breast Cancer Res Treat. 2004 May;85(2):151-9 - PubMed
  42. Clin Cancer Res. 2008 Dec 15;14(24):8027-41 - PubMed
  43. Cancer Chemother Pharmacol. 2005 May;55(5):471-8 - PubMed
  44. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9 - PubMed
  45. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75 - PubMed
  46. Clin Chem. 2009 Oct;55(10 ):1770-82 - PubMed
  47. Cancer. 2009 Mar 1;115(5):952-61 - PubMed
  48. Oncogene. 2006 Mar 13;25(11):1673-8 - PubMed
  49. Lancet Oncol. 2009 Aug;10(8):825-33 - PubMed
  50. J Natl Cancer Inst. 2009 Oct 21;101(20):1370-1 - PubMed
  51. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  52. J Clin Oncol. 2007 Nov 20;25(33):5187-93 - PubMed
  53. J Clin Oncol. 2005 Dec 20;23(36):9312-8 - PubMed
  54. J Steroid Biochem Mol Biol. 1994 Mar;48(4):369-75 - PubMed
  55. J Clin Oncol. 2010 Mar 10;28(8):1287-93 - PubMed
  56. Lancet. 2000 Dec 16;356(9247):2059-63 - PubMed
  57. Br J Cancer. 2009 Sep 15;101(6):875-8 - PubMed
  58. J Clin Oncol. 2010 May 10;28(14):2423-9 - PubMed

Publication Types